COVID Vaccination in DMT-Treated MS Patients: New Data

COVID rates after vaccination are relatively low and cases mild in patients with multiple sclerosis treated with disease-modifying therapies – but vaccine antibody response is lower with anti-CD20 therapies.

Related Keywords

Florida ,United States ,California ,Maryland ,National Harbor ,San Francisco ,Daniel Kantor ,Janice Wong ,Preeti Bajaj ,Rahul Dave ,Bruceac Cree ,Janssen Research ,University Of California ,Genentech ,University Of Virginia College Medicine ,Neuroimmunology Center ,Consortium Of Multiple Sclerosis Centers ,Inova Neurosciences Institute ,Florida Society Of Neurology ,Weill Institute For Neurosciences ,Multiple Sclerosis Centers ,Virginia College ,Medscape Medical ,Florida Society ,Medical Partnership ,Medscape Medical News ,Weill Institute ,Multiple Sclerosis Ms ,Multiple Sclerosis ,Us ,Vaccine ,Disease Modifying Therapy ,Mt ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Biologic Therapy ,Immunomodulator ,Lenalidomide ,Receptors ,Clinical Research ,Clinical Trials ,Linical Studies ,Elderly Concerns Of Older Adults ,Geriatric ,